Hepatocellular Carcinoma Medication

Updated: Sep 29, 2017
  • Author: Luca Cicalese, MD, FACS; Chief Editor: John Geibel, MD, DSc, MSc, AGAF  more...
  • Print
Medication

Medication Summary

Few systemic options exist for patients with hepatocellular carcinoma (HCC). Sorafenib, regorafenib, and nivolumab are the most recent options for patients with unresectable HCC.

Next:

Antineoplastics, Tyrosine Kinase Inhibitor

Class Summary

Tyrosine kinase inhibitors have shown inhibitory activity of membrane-bound and intracellular kinases involved in normal cellular functions and in pathological processes.

Sorafenib (Nexavar)

Sorafenib is a tyrosine kinase inhibitor. It is indicated for unresectable hepatocellular carcinoma.

Regorafenib (Stivarga)

Regorafenib is a tyrosine kinase inhibitor. It is indicated for hepatocellular carcinoma in patients who have been previously treated with sorafenib.

Previous
Next:

PD-1/PD-L1 Inhibitors

Class Summary

PD-1 and related target PD-ligand 1 (PD-L1) are expressed on the surface of activated T cells under normal conditions. PD-L1/PD-1 interaction inhibits immune activation and reduces T-cell cytotoxic activity when bound.

Nivolumab (Opdivo)

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody. It is indicated for hepatocellular carcinoma in patients who have been previously treated with sorafenib.

Previous